ID: ALA2333220

Max Phase: Preclinical

Molecular Formula: C21H21ClN4O2

Molecular Weight: 396.88

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(CNc2c(CO)cnc3c(N(C)C)cc(C#N)cc23)cc1Cl

Standard InChI:  InChI=1S/C21H21ClN4O2/c1-26(2)18-8-14(9-23)6-16-20(15(12-27)11-25-21(16)18)24-10-13-4-5-19(28-3)17(22)7-13/h4-8,11,27H,10,12H2,1-3H3,(H,24,25)

Standard InChI Key:  YMTICTKFJDXTTA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 396.88

Molecular Weight (Monoisotopic): 396.1353

AlogP: 3.94

#Rotatable Bonds: 6

Polar Surface Area: 81.41

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.94

CX LogP: 2.97

CX LogD: 2.85

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.66

Np Likeness Score: -1.01

References

1. Fiorito J, Saeed F, Zhang H, Staniszewski A, Feng Y, Francis YI, Rao S, Thakkar DM, Deng SX, Landry DW, Arancio O..  (2013)  Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.,  60  [PMID:23313637] [10.1016/j.ejmech.2012.12.009]

2. Umar T, Hoda N.  (2015)  Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders,  6  (12): [10.1039/C5MD00419E]

Source

Source(1):

• Scientific Literature